These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21424451)

  • 1. Antibacterial application of engineered bacteriophage nanomedicines: antibody-targeted, chloramphenicol prodrug loaded bacteriophages for inhibiting the growth of Staphylococcus aureus bacteria.
    Vaks L; Benhar I
    Methods Mol Biol; 2011; 726():187-206. PubMed ID: 21424451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted drug-carrying bacteriophages as antibacterial nanomedicines.
    Yacoby I; Bar H; Benhar I
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2156-63. PubMed ID: 17404004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages.
    Yacoby I; Shamis M; Bar H; Shabat D; Benhar I
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2087-97. PubMed ID: 16723570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs against superbugs: private lessons from bacteriophages.
    Brown ED
    Trends Biotechnol; 2004 Sep; 22(9):434-6. PubMed ID: 15331220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11.
    Matsuzaki S; Yasuda M; Nishikawa H; Kuroda M; Ujihara T; Shuin T; Shen Y; Jin Z; Fujimoto S; Nasimuzzaman MD; Wakiguchi H; Sugihara S; Sugiura T; Koda S; Muraoka A; Imai S
    J Infect Dis; 2003 Feb; 187(4):613-24. PubMed ID: 12599078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The bacteriophages and their gene products as antimicrobial agents].
    García E; López R
    Rev Esp Quimioter; 2002 Dec; 15(4):306-12. PubMed ID: 12587035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killing cancer cells by targeted drug-carrying phage nanomedicines.
    Bar H; Yacoby I; Benhar I
    BMC Biotechnol; 2008 Apr; 8():37. PubMed ID: 18387177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental phage therapy against Staphylococcus aureus in mice.
    Capparelli R; Parlato M; Borriello G; Salvatore P; Iannelli D
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2765-73. PubMed ID: 17517843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted filamentous bacteriophages as therapeutic agents.
    Yacoby I; Benhar I
    Expert Opin Drug Deliv; 2008 Mar; 5(3):321-9. PubMed ID: 18318653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating efficacy of bacteriophage therapy against Staphylococcus aureus infections using a silkworm larval infection model.
    Takemura-Uchiyama I; Uchiyama J; Kato S; Inoue T; Ujihara T; Ohara N; Daibata M; Matsuzaki S
    FEMS Microbiol Lett; 2013 Oct; 347(1):52-60. PubMed ID: 23869440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: a comparative approach to conventional DNA vaccine.
    Hashemi H; Bamdad T; Jamali A; Pouyanfard S; Mohammadi MG
    J Virol Methods; 2010 Feb; 163(2):440-4. PubMed ID: 19903497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phage-inspired antibiotics?
    Projan S
    Nat Biotechnol; 2004 Feb; 22(2):167-8. PubMed ID: 14755287
    [No Abstract]   [Full Text] [Related]  

  • 14. Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment.
    Dąbrowska K; Kaźmierczak Z; Majewska J; Miernikiewicz P; Piotrowicz A; Wietrzyk J; Lecion D; Hodyra K; Nasulewicz-Goldeman A; Owczarek B; Górski A
    Future Microbiol; 2014; 9(7):861-9. PubMed ID: 25156375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adapter-directed display: a modular design for shuttling display on phage surfaces.
    Wang KC; Wang X; Zhong P; Luo PP
    J Mol Biol; 2010 Feb; 395(5):1088-101. PubMed ID: 19969002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria.
    Qiu XQ; Wang H; Lu XF; Zhang J; Li SF; Cheng G; Wan L; Yang L; Zuo JY; Zhou YQ; Wang HY; Cheng X; Zhang SH; Ou ZR; Zhong ZC; Cheng JQ; Li YP; Wu GY
    Nat Biotechnol; 2003 Dec; 21(12):1480-5. PubMed ID: 14625561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial drug discovery through bacteriophage genomics.
    Liu J; Dehbi M; Moeck G; Arhin F; Bauda P; Bergeron D; Callejo M; Ferretti V; Ha N; Kwan T; McCarty J; Srikumar R; Williams D; Wu JJ; Gros P; Pelletier J; DuBow M
    Nat Biotechnol; 2004 Feb; 22(2):185-91. PubMed ID: 14716317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study.
    Onsea J; Post V; Buchholz T; Schwegler H; Zeiter S; Wagemans J; Pirnay JP; Merabishvili M; D'Este M; Rotman SG; Trampuz A; Verhofstad MHJ; Obremskey WT; Lavigne R; Richards RG; Moriarty TF; Metsemakers WJ
    Microbiol Spectr; 2021 Dec; 9(3):e0173621. PubMed ID: 34908439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of a novel Staphylococcus aureus bacteriophage, phiMR25, and its therapeutic potential.
    Hoshiba H; Uchiyama J; Kato S; Ujihara T; Muraoka A; Daibata M; Wakiguchi H; Matsuzaki S
    Arch Virol; 2010 Apr; 155(4):545-52. PubMed ID: 20224894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines.
    Vaks L; Benhar I
    J Nanobiotechnology; 2011 Dec; 9():58. PubMed ID: 22185583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.